Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade. 

The Society of Cardiovascular Computed Tomography is cheering as a “huge win” the 2025 CMS payment increase for coronary CTA that more than doubles the current payment and “better aligns with the cost of providing CCTA services." The panel expects the move to bring an increase in CT utilization, more adoption with financial sustainability and greater access in currently underutilized areas.

The new technology, still under development, could help physicians screen patients for diabetes and hypertension with high-speed video recordings. 

SOLVE-TAVI focused on the long-term impact of selecting different second-generation transcatheter heart valves and anesthesia strategies for transfemoral TAVR procedures.

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.

Costs remain a concern, especially for low-volume centers, but robotic-assisted MV repair is associated with short-term outcomes comparable to more conventional techniques.